Drug Profile
Certolizumab pegol biosimilar - Primrose Bio
Alternative Names: PF 688Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Pfenex
- Developer Primrose Bio
- Class Anti-inflammatories; Antirheumatics; Fab fragments; Monoclonal antibodies; Polyethylene glycols
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Crohn's disease; Rheumatoid arthritis
Most Recent Events
- 18 Sep 2023 Primordial Genetics has merged with Pelican Expression Technology to form Primrose Bio
- 01 Oct 2020 Pfenex has been acquired by Ligand Pharmaceuticals
- 28 Jun 2019 No recent reports of development identified for preclinical development in Crohn's-disease in USA (SC, Injection)